Overview
Early-stage venture capital firm backing technology companies addressing widely used services and infrastructure. Life sciences exposure includes its investment in Betteromics, an AI and omics data platform, which exited in 2024.
Unlock the full profileGet the complete company dossier
This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.